Protalix BioTherapeutics (PLX) EBIT Growth (3y) (2013 - 2026)
Powered by 
Analysis
Protalix BioTherapeutics (PLX) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 9.40% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -102.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 6.70% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 8.36% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 89.72% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 24.14% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 44.34% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -96.48% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Protalix BioTherapeutics | 218.36 Mn | 177.71 Mn | 12.13 Mn | -38.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -38.84% |
| Mar 31, 2026 | 119.66% |
| Dec 31, 2025 | -23.13% |
| Sep 30, 2025 | 38.94% |
| Jun 30, 2025 | 30.30% |
| Mar 31, 2025 | -30.39% |
| Dec 31, 2024 | 48.33% |
| Sep 30, 2024 | 60.28% |
| Jun 30, 2024 | 35.79% |
| Mar 31, 2024 | -9.44% |
| Dec 31, 2023 | -58.45% |
| Sep 30, 2023 | 9.92% |
| Jun 30, 2023 | 123.18% |
| Mar 31, 2023 | -36.15% |
| Dec 31, 2022 | -46.34% |
| Sep 30, 2022 | -26.49% |
| Jun 30, 2022 | 1.83% |
| Mar 31, 2022 | 30.35% |
| Dec 31, 2021 | -15.83% |
| Sep 30, 2021 | 20.43% |